Connecticut Innovations (CI), the strategic venture capital arm of the state of Connecticut, has reported its strongest financial performance to date, closing fiscal year 2026 with record cash returns from portfolio investments.
The organization generated $66.5 million in proceeds from successful company exits, while total proceeds from all investment-related activities reached $76.1 million.
Strong Returns Highlight Successful Investment Strategy
The record-setting performance reflects a series of high-value exits across CI’s investment portfolio, underscoring the organization’s strategy of backing innovative startups with long-term growth potential.
The results mark a milestone for the New Haven-based investor, demonstrating both strong financial returns and the increasing maturity of companies supported through its funding programs.
The proceeds were fueled by multiple high-profile transactions that delivered substantial value for the investment portfolio during the fiscal year.
Major Portfolio Companies Deliver Landmark Exits
Several of Connecticut Innovations’ portfolio companies achieved transformative milestones that contributed significantly to the year’s record performance.
Among the standout transactions was Halda Therapeutics, which was acquired by Johnson & Johnson in a deal valued at $3.05 billion.
Another notable success came from Quantum Circuits Inc., which was purchased by D-Wave Quantum for $550 million.
Meanwhile, Veradermics reached the public markets through a successful listing on the New York Stock Exchange, raising $256.3 million in its initial public offering.
These transactions collectively strengthened CI’s financial results while highlighting the commercial success of companies supported during their early stages.
Continued Investment in Emerging Businesses
Despite recording substantial returns, Connecticut Innovations maintained an aggressive investment pace throughout fiscal year 2026.
During the period ending June 30, 2026, the organization invested $59.3 million across 75 early-stage companies and venture capital funds.
Those investments also attracted significant participation from external investors, leveraging approximately $1.2 billion in additional capital.
The influx of outside funding demonstrates continued confidence in the startups and technology ventures supported by CI.
Supporting Innovation Beyond Capital
Beyond providing funding, Connecticut Innovations continues to position itself as a strategic partner for entrepreneurs by offering business guidance, operational support, and introductions to corporate partners and investors.
Its investment approach combines equity and debt financing with hands-on assistance designed to help emerging companies scale more effectively.
Leadership Focused on Long-Term Growth
Under the leadership of Chief Executive Officer Matt McCooe, Connecticut Innovations has expanded its role as the state’s leading source of venture financing for innovative businesses.
The latest fiscal results reinforce the organization’s commitment to fostering entrepreneurship, accelerating commercialization, and generating both economic growth and strong investment returns across Connecticut’s innovation ecosystem.
What the Record Results Mean
The fiscal year 2026 performance demonstrates the growing impact of Connecticut Innovations’ investment strategy.
Record proceeds, successful exits, sustained investment activity, and the ability to attract over $1.2 billion in co-investment capital indicate that the organization is strengthening Connecticut’s position as a hub for high-growth technology and life sciences companies while continuing to deliver measurable financial success.
